BDX BECTON DICKINSON & CO
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 10795 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.2%
TTM net income YoY-40.6%
TTM EPS YoY-39.5%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR-17.3%
Margins
Gross margin46.4%
Operating margin9.6%
Net margin4.5%
FCF margin13.1%
EBITDA margin21.6%
Returns
ROE3.8%
ROA1.8%
ROIC (approx.)4.2%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets51.9%
Debt / equity0.69x
Current ratio0.87x
Interest coverage3.40x
Cash quality & payout
Operating cash flow / net income3.67x
Accruals ratio-4.8%
Payout ratio124.5%
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B |
| Cost of revenue | $11.91B | $11.05B | $11.20B | $10.39B | $10.50B |
| Gross profit | $9.93B | $9.12B | $8.17B | $8.48B | $8.63B |
| R&D expense | $1.26B | $1.19B | $1.24B | $1.26B | $1.28B |
| SG&A expense | $5.28B | $4.86B | $4.72B | $4.71B | $4.72B |
| Operating income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B |
| Interest expense | $613.00M | $528.00M | $452.00M | $398.00M | $469.00M |
| Pretax income | $1.88B | $2.00B | $1.66B | $1.78B | $1.69B |
| Income tax | $203.00M | $300.00M | $132.00M | $148.00M | $88.00M |
| Net income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B |
| EBITDA | $5.04B | $4.68B | $4.40B | $4.51B | $4.48B |
| EPS (basic) | 5.83 | 5.88 | 4.97 | 5.93 | 6.92 |
| EPS (diluted) | 5.82 | 5.86 | 4.94 | 5.88 | 6.85 |
| Dividends declared per share | 4.16 | 3.80 | 3.64 | 3.48 | 3.32 |
| Weighted avg. shares (diluted) | 288.51M | 291.01M | 288.39M | 287.36M | 292.09M |
| Balance sheet | |||||
| Cash & equivalents | $567.00M | $1.79B | $1.48B | $1.16B | $2.39B |
| Receivables | $2.40B | $3.03B | $2.53B | $2.19B | $2.35B |
| Inventory | $3.15B | $3.84B | $3.27B | $3.22B | $2.74B |
| Current assets | $9.26B | $10.47B | $8.68B | $8.14B | $8.84B |
| PP&E, net | $6.38B | $6.82B | $6.56B | $6.01B | $6.00B |
| Goodwill | $25.96B | $26.46B | $24.52B | $24.62B | $23.89B |
| Intangibles | $9.23B | $10.87B | $10.90B | $12.26B | $12.73B |
| Total assets | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B |
| Current liabilities | $8.31B | $8.96B | $6.64B | $7.81B | $6.63B |
| Short-term debt | $1.56B | $2.17B | $1.14B | $2.18B | $500.00M |
| Long-term debt | $17.62B | $17.94B | $14.74B | $13.89B | $17.11B |
| Total debt | $19.18B | $20.11B | $15.88B | $16.07B | $17.61B |
| Total liabilities | $29.93B | $31.40B | $26.98B | $27.65B | $30.19B |
| Shareholders' equity | $25.39B | $25.89B | $25.80B | $25.28B | $23.68B |
| Net debt | $18.61B | $18.32B | $14.40B | $14.91B | $15.22B |
| Cash flow statement | |||||
| Operating cash flow | $3.43B | $3.84B | $2.99B | $2.47B | $4.13B |
| Capital expenditure | $760.00M | $725.00M | $874.00M | $973.00M | $1.19B |
| Free cash flow | $2.67B | $3.12B | $2.12B | $1.50B | $2.93B |
| Investing cash flow | -$818.00M | -$5.51B | -$716.00M | -$3.22B | -$1.84B |
| Financing cash flow | -$3.62B | $2.09B | -$1.96B | -$736.00M | -$3.31B |
| Depreciation & amortization | $2.46B | $2.29B | $2.29B | $2.23B | $2.23B |
| Stock-based compensation | $258.00M | $247.00M | $259.00M | $233.00M | $229.00M |
| Dividends paid | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B |
| Share buybacks | $1.00B | $500.00M | $0 | $500.00M | $1.75B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.